These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 39343635)

  • 1. EZHIP's role in diffuse midline glioma: echoes of oncohistones?
    Cassim A; Dun MD; Gallego-Ortega D; Valdes-Mora F
    Trends Cancer; 2024 Sep; ():. PubMed ID: 39343635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones.
    Sarthy JF; Meers MP; Janssens DH; Henikoff JG; Feldman H; Paddison PJ; Lockwood CM; Vitanza NA; Olson JM; Ahmad K; Henikoff S
    Elife; 2020 Sep; 9():. PubMed ID: 32902381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2.
    Jain SU; Rashoff AQ; Krabbenhoft SD; Hoelper D; Do TJ; Gibson TJ; Lundgren SM; Bondra ER; Deshmukh S; Harutyunyan AS; Juretic N; Jabado N; Harrison MM; Lewis PW
    Mol Cell; 2020 Nov; 80(4):726-735.e7. PubMed ID: 33049227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.
    Pun M; Pratt D; Nano PR; Joshi PK; Jiang L; Englinger B; Rao A; Cieslik M; Chinnaiyan AM; Aldape K; Pfister S; Filbin MG; Bhaduri A; Venneti S
    Acta Neuropathol Commun; 2023 Feb; 11(1):25. PubMed ID: 36759899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H3F3A K27M Mutations Drives a Repressive Transcriptome by Modulating Chromatin Accessibility, Independent of H3K27me3 in Diffuse Midline Glioma.
    Bhattarai S; Hakkim FL; Day CA; Grigore F; Langfald A; Entin I; Hinchcliffe EH; Robinson JP
    bioRxiv; 2024 May; ():. PubMed ID: 38798502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
    Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
    Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.
    Jain SU; Do TJ; Lund PJ; Rashoff AQ; Diehl KL; Cieslik M; Bajic A; Juretic N; Deshmukh S; Venneti S; Muir TW; Garcia BA; Jabado N; Lewis PW
    Nat Commun; 2019 May; 10(1):2146. PubMed ID: 31086175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
    Jenseit A; Camgöz A; Pfister SM; Kool M
    Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone H3 K27M-mediated regulation of cancer cell stemness and differentiation in diffuse midline glioma.
    Sharma M; Barravecchia I; Magnuson B; Ferris SF; Apfelbaum A; Mbah NE; Cruz J; Krishnamoorthy V; Teis R; Kauss M; Koschmann C; Lyssiotis CA; Ljungman M; Galban S
    Neoplasia; 2023 Oct; 44():100931. PubMed ID: 37647805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
    Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
    Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes.
    Ajuyah P; Mayoh C; Lau LMS; Barahona P; Wong M; Chambers H; Valdes-Mora F; Senapati A; Gifford AJ; D'Arcy C; Hansford JR; Manoharan N; Nicholls W; Williams MM; Wood PJ; Cowley MJ; Tyrrell V; Haber M; Ekert PG; Ziegler DS; Khuong-Quang DA
    Sci Rep; 2023 Mar; 13(1):3775. PubMed ID: 36882456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation.
    Castel D; Kergrohen T; Tauziède-Espariat A; Mackay A; Ghermaoui S; Lechapt E; Pfister SM; Kramm CM; Boddaert N; Blauwblomme T; Puget S; Beccaria K; Jones C; Jones DTW; Varlet P; Grill J; Debily MA
    Acta Neuropathol; 2020 Jun; 139(6):1109-1113. PubMed ID: 32193787
    [No Abstract]   [Full Text] [Related]  

  • 13. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study.
    Garibotto F; Madia F; Milanaccio C; Verrico A; Piccardo A; Tortora D; Piatelli G; Diana MC; Capra V; Garrè ML; Rossi A; Morana G
    Front Oncol; 2020; 10():795. PubMed ID: 32582540
    [No Abstract]   [Full Text] [Related]  

  • 15. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
    Vuong HG; Ngo TNM; Le HT; Dunn IF
    J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
    Mariet C; Castel D; Grill J; Saffroy R; Dangouloff-Ros V; Boddaert N; Llamas-Guttierrez F; Chappé C; Puget S; Hasty L; Chrétien F; Métais A; Varlet P; Tauziède-Espariat A
    Acta Neuropathol Commun; 2022 Sep; 10(1):137. PubMed ID: 36104744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse midline glioma H3K27M mutation in adult: A case report.
    Bhattarai AM; Mainali G; Jha P; Karki P; Adhikari A; Pandit A; Bhattarai AM
    Ann Med Surg (Lond); 2022 Apr; 76():103567. PubMed ID: 35495373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis.
    Dhar S; Gadd S; Patel P; Vaynshteyn J; Raju GP; Hashizume R; Brat DJ; Becher OJ
    Acta Neuropathol Commun; 2022 Apr; 10(1):47. PubMed ID: 35395831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of H3K27M-mutant diffuse gliomas with a non-midline location.
    Guidara S; Seyve A; Poncet D; Leonce C; Bringuier PP; McLeer A; Sturm D; Cartalat S; Picart T; Ferrari A; Hench J; Frank S; Meyronet D; Ducray F; Barritault M
    J Neurooncol; 2024 Sep; 169(2):391-398. PubMed ID: 38937309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.
    Ocasio JK; Budd KM; Roach JT; Andrews JM; Baker SJ
    Cancer Metastasis Rev; 2023 Jun; 42(2):367-388. PubMed ID: 37119408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.